Sotoracib (AMG510) is a first-generation targeted drug

Sotoracib (AMG510) is a small molecule that selectively and irreversibly targets KRAS G12C. It is a third-generation tyrosine kinase inhibitor (TKI) targeted drug. Sotoracib is used to treat non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body after treatment with at least one cancer drug.

The most common adverse reactions of sotorasiib(≥ 20%) are diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity and cough. The most common laboratory abnormalities (≥ 25%)are lymphopenia, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urinary protein, and decreased sodium. Avoid coadministration of sotoraxib with proton pump inhibitors (PPIs) and H2 receptor antagonists. If the use of acid-reducing agents cannot be avoided, please use topical Take LUMAKRAS4 hours before or 10 hours after antacids. Avoid coadministration with strong CYP3A4 inducers. Avoid coadministration with CYP3A4 substrates as minimal concentration changes may result in therapeutic failure of the substrate. If coadministration cannot be avoided, adjust the substrate dosage according to its prescribing information. Avoid coadministration with P-gpsubstrates as minimal concentration changes may result in severe toxicity. If coadministration cannot be avoided, reduce the substrate dosage according to its prescribing information. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.